The AZA-PD study: a clinical trial of azathioprine in Parkinson's - November 2020

A research group in Cambridge - supported by The Cure Parkinson's Trust and Cambridge Centre for Parkinson-Plus - will be conducting a clinical trial to test whether suppressing the immune system can help to slow the progression of Parkinson's.

Diabetes Medications Impacts Risk of Parkinson’s - October 2020

In a recent study supported by The Cure Parkinson's Trust, researchers concluded that the elevated risk of Parkinson’s disease in patients with diabetes might be mitigated depending on the type of drugs prescribed to treat type 2 diabetes.

The PD-STAT/Simvastatin study results - September 2020

The results of a large Cure Parkinson's Trust-funded clinical trial were released, evaluating the disease-modifying potential of the cholesterol-lowering drug simvastatin in people with Parkinson's. The results indicate that the treatment does not have any impact of the progression of the condition.

Drug Shows Signs of Efficacy in Early Stage Parkinson’s - September 2020

In April the results of a major clinical trial - called the PASADENA study - were announced. Although the results indicated that the trial had not achieved a positive result based on a predetermined measure of success, the investigators conducting the study indicated that there were ‘signals of efficacy‘ in the data.

The Epigenetics of Parkinson's. - Aug 2020

In their epigenetics study of Parkinson's, researchers at the Van Andel Institute (Michigan) have identified a “master regulator” gene switch that may protect the brain from neurodegeneration.

A Biomarker for Parkinson's? - Aug 2020

A research report published this week, highlights a protein that could represent the first 'biomarker' for Parkinson's progression.

DENALI and Biogen Team Up Against LRRK2 - Aug 2020

A collaborative deal between Denali and Biogen brings a new potential Parkinson's treatment a step closer.

MODAG: Positive Phase 1 Results of Potential New Parkinson's Drug - Aug 2020

Supported by CPT, German Biotech company MODAG have announced positive results from their phase 1 clinical trial of Anle138b for Parkinson's.

An Overview of Drug Development for Parkinson's - Aug 2020

Recently published research, conducted by Parkinson's research advocates and CPT, presents an encouraging overview of current agents in the pipeline for the treatment of Parkinson's. This report represents one of the first classifications and in-depth analysis of the Parkinson's clinical trials arena.

Helping the Research Community Restart their Studies - Aug 2020

As researchers in the field of Parkinson’s take steps to invite patients back to take part in face-to-face studies, we'd like to hear your views about returning to participate in research.

CPT's Dr Richard Wyse Co-edits Prestigious Cochrane Report - Aug 2020

CPT's Dr Richard Wyse is the co-editor of a recent Cochrane Report on GLP‐1 receptor agonists and their potential use in treating Parkinson's Disease. Read the report...

Further Evidence of Neuroprotection of Simvastatin in Parkinson's - July 2020

Researchers in Israel have recently published an interesting new study which provides a novel insight and further independent support for simvastatin which CPT is clinically testing in people with Parkinson's.

Blood Plasma Infusions for Parkinson's - July 2020

Research has shown that infusions of blood plasma from young animal models can improve the health of older animal models, and a recent study of plasma infusions in people with Parkinson's warrants further investigations.

Parkinson's: the Absense of Appendixes & Tonsils - July 2020

Recent research of large data in Sweden has shown removal of tonsils and appendixes reduces the risk of Parkinson's.

Astrocytes to Dopamine Neurons in One Step - June 2020

A Chinese research group have shown that 'helper cells' in the brain called astrocytes can be converted to nerve cells, which then can go on to produce dopamine - the brain chemical lost in Parkinson's. This is exciting news, but further research is needed.

A Greater Role for the Parkinson's GBA Gene Protein? - June 2020

A better knowledge of variations in our DNA could not only provide insights into the underlying biology of Parkinson's but could also help us understand why we are affected differently, and how best to treat the disease.

Dexamethasone for COVID - and Perhaps Parkinson's? - June 2020

A corticosteroid medication used to reduce inflammation in conditions such as arthritis and asthma has shown to help COVID-19 patients - and there is a growing body of evidence to suggest that these medications may also be useful in the treatment of Parkinson's

Phase 1 Results for a Parkinson's Vaccine - June 2020

The results of a phase l trial testing a potential vaccine for Parkinson's have been published. Using the body's own immune system to start developing antibodies (immunotherapy) this potential treatment targets a toxic protein called alpha-synuclein thought to be a contributing factor in Parkinson's.

Nerve Growth Factors and Parkinson's - June 2020

For some considerable time CPT has been interested in nerve growth factors or 'neurotrophic' factors for Parkinson's. GDNF, CDNF and C-CDNF are three interesting candidates and our research work within this field continues with drive and urgency.

Multi-Arm Multi-Stage - a New Approach to Clinical Trials - May 2020

Dr Camille Carroll of Plymouth University, a member of our International Linked Clinical Trials (iLCT) committee, has led a group of researchers in exploring a platform for conducting Multi-Arm Multi-Stage clinical trials for Parkinson's.

Fox Insight Launches COVID-19 Survey - April 2020

At present there is little or no research being undertaken on the impact of COVID-19 on the Parkinson's community. Now, Fox Insight has stepped up to the plate to facilitate this important emerging area of research.

Further Support for the 'Repurposed' Simvastatin - April 2020

Statins are a well characterised class of medication that are used to lower cholesterol levels in the body. Evidence strongly suggests certain statins have been for use as a potential treatment for Parkinson's, this particularly applies to a statin called simvastatin

3P: Parkinson’s Postdoc Program Seminars April 2020

Calling early career scientists!
Feeling socially distanced? Maybe quarantined? Wondering what you can do to further your career during this time? How about presenting and discussing your research with other early career neuroscientists who are in the same boat!

A Better Delivery of Dopamine - March 2020

Lower levels of dopamine are associated with the motor symptoms of the condition - slowness and rigidity of movement. New research, led by Prof. David Devos, proposes a continuous delivery of a more stable form of dopamine directly into the brain.

Time to Re-nurture Neurturin? - March 2020

Results of a disappointing clinical trial in 2013 testing a gene therapy for Parkinson's have been re-investigated with some new and important implications for future trials in the field.

Multi-Arm Multi-Stage Trials for Parkinson's - March 2020

Most clinical trials involve a single therapy, being tested against a 'placebo' or control treatment for a fixed period of time. The MAMS study technique explores a potential new trial design for Parkinson's

Exenatide: Further Studies Initiated - March 2020

The Cure Parkinson's Trust is encouraged to see the growing field of study of exenatide in Parkinson's.

Identifying People with Parkinson’s Best Suited to Benefit from Genetic Targeted Therapies - March 2020

CPT recently approved funding for Prof. Antony Cooper to find people with idiopathic Parkinson’s who could benefit from new therapies being developed for genetic forms of the condition, particularly GBA Parkinson's.

Herantis Pharma: Phase 1/2 CDNF Topline Results - February 2020

Herantis Pharma Plc have announced that their ongoing Phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint

Earlier Diagnosis and Treatment of Dementia in Parkinson's - February 2020

Recently published research from UCL suggests monitoring of levels of iron in people with Parkinson's may help with early diagnosis and earlier treatment of dementia.

GDNF and Cell Transplantation: Dual therapies for Parkinson's - February 2020

Scientists in Australia have recently published pre-clinical research exploring multiple treatment approaches for Parkinson's, in particular using GDNF alongside cell replacement therapy.

The Minnesota UDCA Clinical Study - February 2020

Recently, researchers in Minnesota (USA) published the results of a small pilot clinical trial investigating the safety of Ursodeoxycholic acid (or UDCA) in Parkinson's.

UDCA and Laboratory Cell-Based Parkinson's - February 2020

Researchers at Sheffield and Oxford Universities have recently published research exploring 'subtypes' of Parkinson's in cell-culture studies, which has highlighted a drug that The Cure Parkinson's Trust is clinically testing.

Similarities between Alzheimer's and Parkinson's - February 2020

Two groups recently published independent journal articles suggesting that a genetic variation associated with Alzheimer's might also have an important influence in Parkinson's.

New Developments In Diabetes Drugs for Parkinson's - January 2020

At the forefront of treatments for diabetes is a class of drug called glucagon-like peptide 1 receptor (GLP-1R) agonists. There is now considerable evidence that suggest GLP-1R diabetes drugs could potentially be used in the treatment of Parkinson's.

The Bydureon Phase lll Trial: Supplementary Substudies - January 2020

The Cure Parkinson's Trust and the Van Andel Institute are delighted to be supporting two sub-studies led by Prof. Tom Foltynie within the important Bydureon phase lll trial.

Ambroxol in Parkinson's: Results of Phase ll Trial Published - January 2020

The Cure Parkinson's Trust (CPT) is delighted to announce the publication of the results of a Phase II clinical trial evaluating ambroxol as a potential treatment to slow the progression of Parkinson’s.

Review 2019: Research Highlights

Clinical Trial for Anle138b - December 2019

A drug, Anle138b, previously shown to rescue neurons in pre-clinical models of alpha synuclein-associated Parkinson's, is now being trialled in humans.

IPDGC 2019: London December 2019

Over 150 researchers attended this two-day conference focused on improving our understanding of the genetics of Parkinson's, sponsored by The Cure Parkinson's Trust.

GP2: Global Parkinson's Genetics Program - December 2019

Sergey Brin recently founded the ASAP initiative (Aligning Science Across Parkinson's) and more recently announced the Global Parkinson's Genetics Program (GP2).

Keeping Pace with LRRK2 and GCase - December 2019

New research from Northwestern University in Chicago suggests that rather than being targeted towards individuals with LRRK2- or GBA-associated Parkinson's, novel therapies in these fields may be beneficial for others in the wider Parkinson's affected community.

A Sub-Study Investigating Azathioprine in Parkinson's - December 2019

In Parkinson’s there appears to be an over-abundance of inflammatory cells in the brain. This study will examine how azathioprine impacts this inflammation to determine whether this drug could be a future treatment for Parkinson's

Nilotinib Does Not Show Promise for Benefit in Phase II Nilotinib for Parkinson’s Disease (NILO-PD) Trial

Though Safe and Tolerable, Nilotinib Does Not Show Promise for Benefit in Phase II Nilotinib for Parkinson’s Disease (NILO-PD) Trial

Accelerating Medicines Partnership for Parkinson’s - AMP-PD - November 2019

The US National Institute of Health (NIH) have recently announced the opening of a vast new data portal for Parkinson's research.

Genetic Manipulators of Alpha Synuclein - November 2019

A recently published study has identified a gene, DCLK1, as an important regulator of alpha synuclein.

Ambroxol: Further Validation for Potential in Parkinson's - November 2019

Small variations in DNA are associated with some cases of Parkinson's. A recent study of brain tissue finds certain genetic factors strongly associated with the incidence of Parkinson's and gives further validation to a CPT trial.

A New Enzyme to Inhibit LRRK2 - November 2019

Researchers in Dundee and Stanford (USA) have identified a novel method of reducing the hyperactivity of the gene mutation in LRRK2, a major cause of familial and sporadic cases of Parkinson's...

Another Ambroxol-like Drug for Treating Parkinson's? - October 2019

The findings of this new study suggest that enhancing cellular 'GCase' activity may be beneficial to both people with genetic variants of Parkinson's and those with no obvious genetic influence...

Phase ll Clinical Trial to Explore Experimental K0706 in Early Parkinson's - Oct 2019

Sun Pharma Advanced Research Company (SPARC) is conducting a Phase ll clinical trial (PROSEEK) to evaluate the safety and effectiveness of its experimental c-Abl inhibitor, K0706, in people with early Parkinson’s disease.

MIRO - A New Biomarker for Parkinson's? - October 2019

Researchers at Stanford University in the US looking for new biomarkers of Parkinson's, recently identified a protein called MIRO that in initial data very accurately identifies people with the condition...

The Simvastatin Study Protocol - October 2019

The Cure Parkinson's Trust (CPT) is co-funding the ongoing PD-STAT clinical trial evaluating the disease modifying potential of the cholesterol lowering drug simvastatin in our Linked Clinical Trials programme. The trial protocol has recently been published...

The Bydureon Phase lll Trial to Begin Recruiting - October 2019

The next phase of the Exenatide-PD clinical trial will begin recruiting to determine, in a larger cohort, whether this diabetes treatment can slow down disease progression in Parkinson’s...

LRRK2 - Parkinson's, Leprosy, and Crohn’s - October 2019

Researchers in Ottawa have announced a new discovery associated with the LRRK2 genetic form of Parkinson's...

'Voyager' Recruits Patients for Phase 2 Gene Therapy Delivery - September 2019

Voyager Therapeutics announced it is recruiting participants for the company’s Phase 2 trial of gene therapy, VY-AADC02, for advanced Parkinson’s enrolling in US...

Microglia - Why They Are Important in the Parkinsonian Brain - August 2019

In this study, researchers demonstrate the importance of microglia (the immune cells in the brain) to the transfer of the Parkinson's-associated protein alpha synuclein in the brain. They suggested that pharmacological regulation of neuroinflammation could represent a future therapy for Parkinson's...

The BRAIN Tapping Test Goes Mobile - August 2019

Researchers at UCL have recently published a study validating a mobile device test which could continually monitor individuals with Parkinson's...

Bayer Buys Blue Rock - August 2019

Bayer pharmaceutical has bought BlueRock Therapeutics which could have some important implications for the Parkinson's community...

From Dreams to Parkinson's - July 2019

Professor Michele Hu has published an interesting article providing an overview of the 'prodromal phase' or the period before diagnosis in Parkinson's..

The Appendix and Parkinson's - July 2019

Although its exact role isn’t yet clear because findings have been conflicting, in this easy-to-read overviewthe link between the appendix and risk of developing Parkinson's is discussed...

The Rationale for the TRANSEURO Study - July 2019

The TRANSEURO study is being funded by The Cure Parkinson's Trust and is investigating cell transplantation as a restorative therapy for people with Parkinson's. In this article, Prof Roger Barker explains the rational behind the trial design...

More Evidence that Parkinson's Originates in the Gut - July 2019

A new study published in the journal Neuron has found more evidence that Parkinson's starts in cells in the gut and journeys to the brain via the body's neurons.

New Drug to Target Alpha-Synuclein - July 2019

Scientists at Dundee University have partnered with the Korean-based Bukwang Pharmaceutical Company in an effort to develop a drug which blocks the enzyme USP8, the enzyme prevents the natural breakdown of the toxic protein alpha-synuclein...

Anle-138b - New Research Suggests Neuroprotection - June2019

Recently published new research by UK scientists - supported by The Cure Parkinson's Trust - suggest a new treatment that breaks down toxic protein aggregates could be neuroprotective in Parkinson's...

'Cooling' Inflamed Brains in Parkinson's - May 2019

When cells in the body become unwell or injured, they release proteins that inform the body of their stricken situation. These activate the release of further signalling proteins called inflammasomes...

The G-Force PD Meeting with Update Seminar - May 2019

G-Force PD is a global initiative created to bring cell based therapies to people with Parkinson's. This April, on World Parkinson's Day, the G-Force Steering Committee convened in Cambridge for their fifth annual meeting, supported by CPT. This was followed by presentations of the latest cell based therapy research updates...

Isradipine - Clinical Trial Results - May 2019

A study of a blood pressure drug does not show any benefit for people with Parkinson's, according to findings presented at the American Academy of Neurology's Annual Meeting in Philadelphia, May 2019...

GDNF Gene Therapy Clinical Trial - 2019

At the recent annual American Association of Neurological Surgeons meeting, researchers presented the results of a Phase I clinical trial designed to test the safety and tolerability of a gene therapy approach for GDNF in Parkinson's.

The G-Force PD Meeting with Update Seminar - April 2019

G-Force PD is a global initiative created to bring cell based therapies to people with Parkinson's. This April, on World Parkinson's Day, the G-Force Steering Committee convened in Cambridge for their fifth annual meeting, supported by CPT. This was followed by a presentation seminar by the Steering Committee...

The ADPD Conference - Lisbon 2019 

The 14th​ International Conference on Alzheimer's and Parkinson's Diseases (or ADPD meeting) was held in Lisbon, Portugal in March 2019. This five day event was attended by over 4000 researchers, including CPT's Deputy Director of Research, Dr Simon Stott. Find out how Simon got on...

IPDGC: The Genetics of Parkinson's - April 2019

The International Parkinson Disease Genomics Consortium (or IPDGC) was set up in 2009 to collect DNA from enough people with (and without) Parkinson’s to allow for researchers to be confident to identify all the genetic risk factors for Parkinson’s. The group has an annual meeting and our Deputy Director of Research, Dr Simon Stott, was invited to attend the meeting. Find out more from Simon...

'Cooling' Inflamed Brains in Parkinson's - April 2019 

When cells in the body become unwell or injured, they release proteins that inform the body of their stricken situation. These activate the release of further signalling proteins called inflammasomes...

Diag'nose'ing Parkinson's - Is a Person's Aroma a Sign? - March 2019

A person termed a 'Super Smeller' has demonstrated her ability to pin-point people with Parkinson's Disease simply by smelling their natural aroma. This super 'hyperosmic' ability has helped inform researchers on potential earlier diagnosis...

The GDNF trial - the facts

Liver Drug UDCA to be Trialled in People with Parkinson's - February 2019

A drug used to treat liver disease is being trialled in people with Parkinson's...

Follow-Up Study Suggests Potential Measure of Target Engagement - Jan 2019

In this exciting study, Professor Tom Foltynie and colleagues have analysed 'exosomes' - small brain cell-derived sacks or 'vesicles' - in follow-up research from the recent Exenatide study...


Dopamine Neurons That Are Resistant to Parkinson's? - Dec 2018

Scientists at the MRC Centre for Regenerative Medicine (University of Edinburgh) led by Dr Tilo Kunath have taken a key step towards improving an emerging class of treatments for Parkinson’s. The advance could markedly improve a next generation of therapies for the condition...

Inosine Trial to End Early - Dec 2018

Researchers at the Michael J Fox Foundation recently announced that SURE-PD3, a Phase III clinical trial evaluating the potential of Inosine to slow Parkinson's progression, will end earlier than planned.

Stem Cell Therapies - Research Update

Although the underlying cause of Parkinson's is unknown, scientists do know that Parkinson's results from the impairment and loss of dopamine producing cells in an area of the brain called the substantia nigra.

It stands to reason therefore that replacement of those cells is a viable and potentially potent treatment method.

A Vaccine for Parkinson's - Developments in Immunotherapy - Nov 2018

When misfolded, the protein alpha-synuclein becomes toxic to neurons and is a key pathological culprit in Parkinson’s. It is therefore an important target for disease-modification. Immunotherapy in Parkinson's attempts to use immune cells, and specifically the antibodies they generate, to target misfolded alpha-synuclein to inactivate it.

The Cancer Enzyme Involved in Parkinson's - Nov 2018

Researchers at the Johns Hopkins School of Medicine have published a research report that points not only towards a specific pathway of neurodegeneration for Parkinson's, but also highlights a therapeutic target for which clinically-approved drugs are already available.

'Cooling' Inflamed Brains in Parkinson's - Nov 2018

When cells in the body become unwell or injured, they release proteins that inform the body of their stricken situation. These activate the release of further signalling proteins called inflammasomes...

The Appendix and Parkinson's - Are we Better Off Without One? - Nov 2018

The human appendix was long considered functionless and a bit of an oddity or an accident of evolution. However, a new study published this week suggests that the appendix may be influential in some cases of Parkinson's.

Gene Therapy Approaches for Parkinson's - October 2018

Two biotech companies have recently presented updates in their gene therapy treatment trials. Read more...

Article: Triggers, Facilitators, and Aggravators - Redefining Parkinson’s Disease Pathogenesis - October 2018

A recently published opinion paper by Prof.Patrik Brundin and colleagues proposes a redefinition of the pathogenesis of Parkinsons into three progressive phases...

CPT Featured in The Telegraph - 'Could we be on the brink of a Parkinson's breakthrough?' - October 2018

There is a positive feeling within the Parkinson's research community and this article captures it.

The Linked Clinical Trials Meeting 2018 - September 2018

The international Linked Clinical Trials committee met again in September for its annual assessment and evaluation of multiple drugs and compounds with the potential to modify Parkinson's. Find out more...

Denali Announce Positive LRRK2 Trial Results and Advance to Phase Ib Trial - August 2018

Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation.

Trial Design for Parkinson's Disease Modification - August 2018

Helen Matthews, Deputy CEO, attended a recent summit in New York focused specifically on trial design for disease modification organised by The Michael J. Fox Foundation for Parkinson’s Research.

Drug Repurposing in Parkinson's - August 2018

Given the number of failures and the ever-increasing costs and lengthy processes for drug development, our attention continues to be focused on utilising existing compounds approved for other conditions as novel treatments for Parkinson’s.

Kyoto Team Begin Cell Replacement Trial In Parkinson's - July 2018

Professor Jun Takahashi & colleagues at the University of Kyoto Japan have announced that they are to start the world’s first clinical trial of cells derived from induced pluripotent stem cells in people with Parkinsons.

Cell Replacement Therapies for Parkinson's - Dr Tilo Kunath - July 2018

Dr Tilo Kunath is working with cells derived from people with Parkinson's to understand the underlying causes of the condition; to test drugs that might treat it and to replace those cells which are lost.

Stem Cell Therapies - Research Update - July 2018

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.

Nortriptyline in Parkinson's - the facts

LRRK2 May Play a Role in Idiopathic Parkinson's - July 2018

Abnormally increased kinase activity due to mutations in the leucine-rich repeat kinase 2 (LRRK2) gene is the cause of Parkinson’s in about 3 to 4% of people with Parkinson's however researchers have found that independent of any mutations, LRRK2 may also play a role in idiopathic Parkinson's.

Peptron Announces Data of Sustained Release Exendin-4 for PD - July 2018

Peptron has developed a novel form of the GLP-1 agonist SR-exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide in the brain...

Herantis Announces Non-Invasive Treatment Plan of CDNF - July 2018

Herantis Pharma has announced the initiation of a non-invasive CDNF development programme to broaden the application of CDNF in Parkinson's.

The Lixisenatide Trial - July 2018

Another trial in the promising GLP-1 cohort, this study will evaluate the effect of lixisenatide versus placebo on the progression of motor disability in people with early Parkinson's in order to assess its potential disease-modifying effect.

The Liraglutide Trial - July 2018

This GLP-1 receptor agonist study will test the efficacy and safety of liraglutide in the treatment of people with idiopathic Parkinson's (PD)...

Hypertension Drug Shown to be Neuroprotective in Parkinson's - July 2018

The calcium inhibitor drug Isradipine, which is usually used to treat high blood pressure, has shown neuroprotective effects in Parkinsons.

The 100,000 Genomes Project and Parkinson's - July 2018

The aim of this project is to create a new genomic medicine service for the NHS – transforming the way people are cared for. In time, there is the potential of new and more effective treatments. The project will also enable new medical research. Combining genomic sequence data with medical records is a ground-breaking resource...

Type 2 Diabetes Linked to Higher Rate of Parkinson's - June 2018

The study published today in Neurology is the largest study to date on the link between the two conditions.

Astrocyte Conversion by Microglia is Neuroprotective in PD Models - June 2018

Following the recent exenatide trial results, further studies are the potentially important disease-modifying role of GLP-1's in Parkinson's, this new study examines neuroprotection.

Vitamin B3 Might Have Beneficial Effects for Parkinson's - June 2018

Recently researchers have provided very interesting evidence that a form of vitamin B3, called Nicotinamide Riboside, may have beneficial effects for Parkinson’s.

Axovant Announces Deal for Investigational Gene Therapy Treatment - June 2018

Biotech company, Oxford BioMedica, has agreed on a deal with Axovant Sciences of the US to commercialise its gene therapy for Parkinson’s.

Anti-diabetic Drugs and Their Exciting Potential in Parkinson's - May 2018

Metabolism and energy production in cells are the central links between type II diabetes and Parkinson’s, and common to both these conditions are mitochondrial dysfunction and insulin resistance.

Exenatide - Effects on Non-Motor Symptoms: A Follow Up Analysis - May 2018

Funded by CPT, the recent exenatide trial results have been analysed for non-motor responses with the conclusion that 'exenatide may exert independent effects on mood dysfunction'.

From Genetics to Clinic - May 2018

Evolving genetic discoveries in Parkinson's into trials for disease modifying treatments.

The Gut, The Brain and Parkinson's - May 2018

There is a growing body of evidence which links Parkinson's to the gastrointestinal tract, opening potential new avenues for treatment.

Collaboration to Ensure Research Results are Shared - May 2018

23 members of the Association of Medical Research Charities (AMRC) are working in collaboration to develop and launch a joint publication platform.

Korean-based Pharma Advances Clinical Trial of SR-exenatide in Parkinson's - May 2018

Korean-based firm Peptron recently obtained an exclusive worldwide license from the National Institute on Aging (NIA), a National Institutes of Health (NIH) center, covering the delivery and use of sustained-release (SR) exenatide in the treatment of Parkinson’s and other neurodegenerative disorders.

Precision Medicine: Treating the Sub-groups of Parkinson's - April 2018

Important shifts are taking place in the minds of clinicians, researchers and patients. One potentially important development is that of precision medicine...

Stem Cell Therapies - Research Update - April 2018 update from Professor Roger Barker

What is the Link between Diabetes and Parkinson's - March 2018

Parkinson’s is a complex condition with a variety of causes we don't yet fully understand, and while a small number of cases are associated with genetic mutations, the majority originate from a combination of factors. Understanding the underlying causes of PD is becoming an invaluable route in the discovery of new and promising treatments..

Trial of Repurposed Drug Nilotinib in Parkinson's is Recruiting - March 2018

This study is an example of the potential of repurposing drugs, already approved to treat other conditions, in Parkinson's. This can lead to faster approved therapies, since repurposed drugs have already been tested for safety and tolerability in Phase 1 trials in humans.

Herantis Pharma begins Recruitment for CDNF Trial - February 2018

CDNF is a novel drug candidate for the treatment of neurodegenerative diseases such as Parkinson's. It is a protein present in the body's circulatory system with neuroprotective and neurorestorative properties and is patented internationally by Herantis.

The LRRK2 Gene and Parkinson's and the Link with Crohns Disease - January 2018

Leucine-rich repeat kinase 2 (LRRK2) is a known genetic contributor to Parkinson's disease (PD). Recently, a large genetic study of more than 24,500 people has found that Crohn’s, an inflammatory bowel condition, and genetic forms of PD share variants of the LRRK2 gene.

An Interview with Professor Patrik Brundin - January 2018

Ben Stecher interviews Professor Patrik Brundin - lead at the Center for Neurodegenerative Science at Van Andel Research Institute and co-editor of the Journal of Parkinson's Disease.

Identifying Treatments for Parkinson’s Using Patient-derived Induced Neurons - January 2018

Our research committee has approved funding for a revolutionary technique which uses a person with Parkinson's own skin cells to grow neurons affected by their particular type of this disease to then treat with certain drugs.

Small Molecule Drug Offers Neuroprotection with Promise for PD - December 2017

An international team of researchers has shown that a new small-molecule drug can restore brain function and memory in pre-clinical models of Alzheimer's disease. The drug works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envisage that this drug could also be used to treat Parkinson's.

Stem Cell Therapies - Research Update - December 2017

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Scientists are searching for ways to replace these nerve cells.

Synpromics collaboration with UCL in gene therapy for Parkinson’s - December 2017

Synpromics Ltd is pleased to announce a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system to develop a gene therapy for Parkinson’s.

'Voyager' Recruits Patients for Gene Therapy Delivery - November 2017

Voyager Therapeutics announced it is recruiting participants for the company’s new Phase 1 clinical trial to test a new approach for their gene therapy VY-AADC01 in Parkinson’s patients.

Research Update Meeting - November 2017

Nilotinib Trial Recruitment Underway - November 2017

Recruitment will open on an ongoing basis at a maximum of 25 clinical sites across the United States.

Simvastatin Trial Underway - November 2017

The cholesterol-lowering drug Simvastatin is to be trialled as a potential neuroprotective treatment for Parkinson’s.

Parkinson's and the Beta2-Adrenoreceptor Agonist in Asthma Medication - October 2017

Researchers have found that compounds in certain drugs used in the treatment of asthma, may also have beneficial effects in Parkinson’s disease.

Alpha-synuclein oligomers: a new hope - August 2017

A report part funded by The Cure Parkinson's Trust assesses the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discusses the advances in our understanding of the role of alpha-synuclein in Parkinson’s and current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.

The Association of Pesticide Use and Parkinson's - August 2017

Researchers assessed the influence of occupational pesticide use on the prevalence of Parkinson's Disease in people with information available concerning occupational, residential, and household sources of pesticide exposure.

Breaking News: Diabetes Drug Shows Potential as Disease-Modifying Therapy for Parkinson’s - August 2017

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

Reducing Inflammation in Parkinson's using a Clinically Approved Cancer Drug - August 2017

Based on the wealth of evidence that inflammation plays a key role in diseases of the central nervous system, it is thought this line of treatment using a clinically approved cancer drug has significant potential to slow or stop disease progression in Parkinson's.

FDA Approval of Nilotinib in Collaboration Trial - July 2017

The Cure Parkinson's Trust has collaborated with The Michael J Fox Foundation (MJFF) and the Van Andel Research Institute (VARI) of Grand Rapids, Michigan on the clinical development of nilotinib toward the launch of this clinical trial.

Dogs to be Taught to Sniff Out Parkinson's - July 2017

Dogs could soon be used to sniff out Parkinson’s disease years before symptoms start to show.

Abnormal Protein in Parkinson's Triggers an Immune Response - June 2017

Researchers have found the first direct evidence that autoimmunity -- in which the immune system attacks the body's own tissues -- plays a role in Parkinson's Disease.

Trazodone could be Effective in Slowing Disease Progression in Parkinsons - April 2017

New research study suggests depression treatment could show a positive effect in neurodegenerative brain conditions

'Milestones' in 200 Years of Parkinson's Research - March 2017

Marking the 200th anniversary of the first published description by James Parkinson of the disease that would come to bear his name, the Journal of Parkinson’s Disease has published a special issue that features invited commentaries by those responsible for some of the greatest advances in understanding and treating the disease.

Bowel Cancer Medication could help combat Early-Onset Parkinson's - March 2017

Folinic acid can protect neurons in laboratory models, report scientists. The study suggests that folinic acid, which is used in medications to treat bowel cancer, can also protect neurons associated with Parkinson's.

Discovery of Genetic 'Switch' Could Prevent Symptoms of PD - February 2017

A genetic 'switch' has been discovered by MRC researchers at the University of Leicester which could help to prevent or delay the symptoms of Parkinson's disease.

Acorda announces Positive Phase 3 Clinical Trial Results for the Inhalable Drug CVT-301 - February 2017

Acorda have announced positive topline data from a Phase 3 clinical trial for CVT-301, an investigational therapy studied as a treatment for OFF periods in people with Parkinson’s.

PD Breakthrough Could Come From a Single Protein - January 2017

One single protein could be the key to developing groundbreaking treatment for various neurodegenerative diseases including Parkinson’s.

A Steroid Originally Found in Dogfish Could Treat Parkinson's - January 2017

A naturally-occurring compound has been found to block a process thought to cause Parkinson’s, and target its toxic products, scientists have reported.

Diabetes Drug Slows Experimental Parkinson’s Disease Progression. - December 2016

New data published today shows this drug preserves critical brain function in laboratory models of Parkinson’s.

New Evidence Suggests Parkinson's Might Not Start in The Brain - December 2016

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.

'Gap' found in Brain's Firewall against Parkinson's - October 2016

An NIH-funded animal model study identifies a key player in the progression of Parkinson's.

Vaccine for Parkinson's Reports Positive Results from Boost Study - September 2016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson's protein alpha-synuclein.

Diabetes Drug Focus of New Clinical Trial for Parkinson’s - September 2016

A clinical trial, part of our Linked Clinical Trials programme, is now underway at Cedars-Sinai in Los Angeles to investigate the use of the diabetes drug Liraglutide to slow or stop the progression of Parkinson's.

CPT Collaborates to Assess the Clinical Use of Nilotinib in Parkinson's - July 2016

The Michael J. Fox Foundation, Van Andel Research Institute and The Cure Parkinson’s Trust today announced plans to collaborate on the clinical development of nilotinib in preliminary studies as a treatment for Parkinson’s.

European Commission approves ONGENTYS® (opicapone)

BIAL announced today that its product ONGENTYS® (opicapone) for Parkinsons was approved by the European Commission. BIAL will make ONGENTYS® available for people with Parkinson’s across Europe in 2016 and 2017.

Blocking a Key Enzyme Stops Parkinson's Symptoms in Animal Model

Researchers at Johns Hopkins say they have gleaned two important new clues in the fight against Parkinson's: that blocking an enzyme called c-Abl prevents the disease in an animal model and that a chemical tag on a second protein may signal the disorder's presence and progression.

Researchers Open New Path of Discovery in Parkinson's Disease

Two genes associated with Parkinson's disease are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease, a new study indicates.

Parkinson's Cell Transplants Show Good Reinnervation After 24 Years

A postmortem examination of a patient with Parkinson's who underwent dopaminergic cell transplantation 24 years ago has shown that the transplanted neurons had reinnervated the brain for all that time.

Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic in 2016?

A research paper recently published in the Journal of Parkinson's Disease discusses an impending clinical trial in Parkinson's disease (PD) using parthenogenetic stem cells for transplantation into PD patients.

World First Blood Test for Parkinson's

Researchers at La Trobe University Melbourne, Australia have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.

Our Research Update Meeting April 2016

At our recent research update meeting in April, Prof Roger Barker, Dr Mariah Lelos and CPT's Dr Richard Wyse presented their research news to a packed audience of Parkinson's advocates...